Endocrine therapy is an important component of the adjuvant treatment paradigm for the majority of women with hormone receptor (HR)-positive breast cancer, which accounts for approximately two thirds of cases of breast cancer worldwide. The gene discussed is NR4A1; the disease is breast carcinoma.